Streetwise Expert Interviews

Caroline Corner

Cantor Fitzgerald's Caroline Corner: Cutting-Edge Devices and Diagnostics Deliver Drugs and Profits

Medical technology is not considered a huge-margin investment in the way that the biotech and drug industries are. However, some of today's medtech blurs the line, including hybrid companies developing stem cell and drug-device delivery systems that address complex disease indications ranging from blindness to spinal paralysis. Caroline Corner of Cantor Fitzgerald follows companies with technologies that can both address dire diseases and reap windfalls for investors. In this interview with The Life Sciences Report, Corner brings important names to investors' attention.

(7/29/15) More >
Read More Streetwise Interviews

Play the Gap to Profit from Australia's Undervalued Biotech Gems: John Hester

Two hidden biotech gems, one of which could ride the coattails of a U.S.-based product on a very positive regulatory path, top John Hester's list of Australian investments with upside potential. (7/22/15) More >

Newsletter Briefs

"AEMD has approved products that remove viruses, and is now also targeting breast cancer." (7/29/15) Aethlon Medical Inc. - The Life Sciences Report Interview with Caroline Corner More >

"STEM's spinal program has a good chance of success." (7/29/15) StemCells Inc. - The Life Sciences Report Interview with Caroline Corner More >

"Development of AEMD's Hemopurifier continues to ramp up, and results to date look very encouraging." (7/15/15) Aethlon Medical Inc. - The Life Sciences Report Interview with Brian Marckx More >

"If results from RVX's Phase 3 program are positive, the stock could have a significant revaluation to much higher levels." (7/8/15) Resverlogix Corp. - The Life Sciences Report Interview with Jason Napodano More >

"CYNA is now well funded, NASDAQ-listed and liquid; it isdefinitely among my better ideas as of today." (7/8/15) Cynapsus Therapeutics Inc. - The Life Sciences Report Interview with Jason Napodano More >

"I think a large pharma company would be very interested in CTRV's FV-100." (7/8/15) ContraVir Pharmaceuticals Inc. - The Life Sciences Report Interview with Jason Napodano More >

"BCLI has what looks to be a safe and potentially effective treatment for delaying disease progression in patients with ALS." (7/8/15) BrainStorm Cell Therapeutics Inc. - The Life Sciences Report Interview with Jason Napodano More >

"We believe RGS has the potential to become Australia's next success story in regenerative medicine." (7/1/15) Regeneus Ltd. - The Life Sciences Report Interview with Marcel Wijma More >

Expert Analysis

"We reiterate our Buy rating for CPXX and are raising our target price." (7/26/15) Celator Pharmaceuticals Inc. - Joseph Pantginis, ROTH Capital Partners More >

"CBMG has received two new certifications from the China Food and Drug Administration." (7/27/15) Cellular Biomedicine Group Inc. - Stephen Dunn, LifeTech Capital More >

"The EMA encouraged SNSS to submit an MAA in R/R AML >60 years." (7/24/15) Sunesis Pharmaceuticals Inc. - Matthew Andrews, Wells Fargo Securities More >

"Results of MSB's Phase 2 diabetes trial have been published online." (7/24/15) Mesoblast Ltd. - Marcel Wijma, The Daily Molecule (Van Leeuwenhoeck Research) More >

"INO will collaborate with the European Organization for Research and Treatment of Cancer." (7/23/15) Inovio Pharmaceuticals Inc. - Jason Kolbert, Maxim Group More >

"We continue to believe that 2015 is a year of inflection for STEM." (7/23/15) StemCells Inc. - Jason Kolbert, Maxim Group More >

"We are pleased with the positive data from CPXX's Phase 3 trial." (7/28/15) Celator Pharmaceuticals Inc. - Grant Zeng, Zacks Small-Cap Research More >

"We assume SNSS will file with the EU in Q4 EY/15." (7/23/15) Sunesis Pharmaceuticals Inc. - Hartaj Singh, BTIG Research More >